Form 4: Kalaris Therapeutics Director Acquires Stock Options

Anthony P. Adamis, a director of Kalaris Therapeutics, Inc., was granted stock options to purchase 18,000 shares of common stock.

Summary

• On April 10, 2025, Anthony P. Adamis, a director of Kalaris Therapeutics, Inc., was granted stock options.
• The options allow him to purchase 18,000 shares of common stock at an exercise price of $7.31 per share.
• The options vest in equal monthly installments over three years, from March 18, 2025, through March 18, 2028, contingent upon continuous service.
• The options expire on April 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options being granted to a director, which is a common practice.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of three years with monthly installments is a typical arrangement to ensure long-term commitment.
• The exercise price is usually set at or above the market price of the stock on the grant date.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Kalaris Therapeutics, director, Adamis, beneficial ownership, Form 4, KLRS